Green Coffee Effect on Metabolic Syndrome

Effect of Green Coffee Supplementation on Inflammatory Biomarkers in Obese Patients With Metabolic Syndrome

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05688917

Enrollment

160

Registered

2023-01-18

Start date

2020-09-03

Completion date

2022-09-30

Last updated

2023-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, Metabolic Syndrome, Obesity, Supportive Care

Brief summary

The present study aimed to investigate the effect of green coffee bean extract (GCBE) on the inflammatory biomarkers in obese patients with a metabolic syndrome via analyzing some inflammatory biomarkers as resistin, TNF-α, total sialic acid, homocysteine, high sensitivity C-reactive protein (hs-CRP) and anti-inflammatory cytokine, adiponectin

Detailed description

160 obese patients supplemented with either GCBE capsules (800 mg) daily or placebo for 6 months and advised to take a balanced diet. Blood samples were collected at baseline and after three months of supplementation

Interventions

DIETARY_SUPPLEMENTGreen coffee been extract

supportive treatment

OTHERPlacebo

Placebo capsule

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

DOUBLE (Subject, Investigator)

Masking description

double-blind randomised controlled study

Intervention model description

160 obese patients supplemented with GCBE capsules (800 mg) daily for six months

Eligibility

Sex/Gender

ALL

Age

20 Years to 60 Years

Healthy volunteers

Inclusion criteria

Participants were enrolled if they were * aged 20-60y * waist circumference \>102 cm in male; 88 cm in female * triglycerides ≥150 mg/dL (1.7 mmol/L) * HDL-C\<40 mg/dL (1.03 mmol/L) in males & \<50 mg/dL (1.29 mmol/L) in females * systolic BP ≥ 130 or diastolic BP ≥ 85 mm Hg.

Exclusion criteria

* liver, kidney, coronary artery disease, type I diabetes, autoimmune diseases, cancer, infection, smoking, recent major surgery, routine coffee consumption, pregnancy or breast-feeding, use of anti-inflammatory drugs, corticosteroids, hormone replacement therapy, weight-loss and anti-hypercholesterolemic medications three months or less prior to enrolment

Design outcomes

Primary

Measure	Time frame	Description
TNF-α (pg/mL)	six months	Serum Level
Homocysteine (µmol/L)	six months	Serum Level
Hs-CRP (mg/L)	Six months	Serum Level
Adiponectin (µg/mL)	six months	Serum Level
Resistin (ng/mL)	six months	Serum Level

Secondary

Measure	Time frame	Description
LDL-C (mg/dL)	six Months	calculated according to Friedewald formula.
BMI (kg/m2)	six months	Weight / hight squared.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026